0001140361-23-012619.txt : 20230320
0001140361-23-012619.hdr.sgml : 20230320
20230320184335
ACCESSION NUMBER: 0001140361-23-012619
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230316
FILED AS OF DATE: 20230320
DATE AS OF CHANGE: 20230320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ogden Christopher
CENTRAL INDEX KEY: 0001914523
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 23747461
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD., SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0407
4
2023-03-16
0001501989
CytomX Therapeutics, Inc.
CTMX
0001914523
Ogden Christopher
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., STE. 400
SOUTH SAN FRANCISCO
CA
94080
true
SVP, Finance and Accounting
false
Common Stock
2023-03-16
4
S
0
516
1.9793
D
37772
D
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.
Includes 30,466 restricted stock units.
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
2023-03-20